anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
== Function == This protein is expressed largely in cells possessing a regulated secretory pathway, such as endocrine/neuroendocrine cells and neurons. The intact proSAAS protein, as well as the carboxyy-terminal peptide containing the inhibitory hexapeptide LLRVKR, functions as an inhibitor of prohormone convertase 1/3, which accomplishes the initial proteolytic cleavage of peptide precursors. ProSAAS is further processed at the N- and C-termini into multiple short peptides, leaving the central segment intact. This central, unprocessed portion of the protein may function as a neural- and endocrine-specific chaperone due to its potent ability to block the aggregation of beta amyloid and alpha synuclein in vitro, and to block oligomer cytotoxicity in cells. Recent data show that nigral proSAAS expression blocks the deterioration of the striatonigral pathway in a synuclein rat model of Parkinson's disease. ProSAAS also oligomerizes and undergoes liquid-liquid phase separation. Differential expression of this gene may be associated with obesity.
== Industry == Until September 2009, Holyhead's main industry was the massive aluminium smelter on the outskirts of the town, operated by Anglesey Aluminium, a subsidiary of Rio Tinto. A large jetty in the harbour received ships from Jamaica and Australia, and their cargoes of alumina were transported on a rope-driven conveyor belt running underneath the town to the plant. The jetty is now available to dock visiting cruise ships. The plant relied for its electricity supply on Wylfa nuclear power station, near Cemaes Bay. However, Wylfa was reaching the end of its life and had permission to generate only until 2012. On 18 October 2010, the British government announced that Wylfa was one of the eight sites it considered suitable for future nuclear power stations. Holyhead Port is a major employer, most of the jobs linked to ferry services to Ireland operated by Stena and Irish Ferries. Other significant industrial/transport sector employers in Holyhead include Holyhead Boatyard, Gwynedd Shipping and Eaton Electrical, with the last of these having seen many job losses in 2009. Until the end of 2020 the port, which employs 250 (in 2021), was the second busiest roll-on roll-off port in the UK after Dover with around 450,000 lorries taking ferries to Dublin. Following the Brexit withdrawal agreement, freight traffic from Ireland fell by 50% in January 2021.
Rather than binding specific ligands, olfactory receptors display affinity for a range of odorant molecules, and conversely a single odorant molecule may bind to a number of olfactory receptors with varying affinities, which depend on physio-chemical properties of molecules like their molecular volumes. Once the odorant has bound to the odorant receptor, the receptor undergoes structural changes and it binds and activates the olfactory-type G protein on the inside of the olfactory receptor neuron. The G protein (Golf and/or Gs) in turn activates the lyase – adenylate cyclase – which converts ATP into cyclic AMP (cAMP). The cAMP opens cyclic nucleotide-gated ion channels which allow calcium and sodium ions to enter into the cell, depolarizing the olfactory receptor neuron and beginning an action potential which carries the information to the brain.
Sources: en.wikipedia.org
Inherited – hereditary motor neuropathies, Charcot–Marie–Tooth disease, and hereditary neuropathy with liability to pressure palsy Acquired – diabetes mellitus, vascular neuropathy, alcohol use disorder, vitamin E deficiency, and vitamin B12 deficiency
Collenchyma (Greek, Colla means gum; enchyma means infusion) is a living tissue of primary body like Parenchyma. Cells are thin-walled but possess thickening of cellulose, water and pectin substances (pectocellulose) at the corners where a number of cells join. This tissue gives tensile strength to the plant and the cells are compactly arranged and have very little inter-cellular spaces. It occurs chiefly in hypodermis of stems and leaves. It is absent in monocots and in roots. Collenchymatous tissue acts as a supporting tissue in stems of young plants. It provides mechanical support, elasticity, and tensile strength to the plant body. It helps in manufacturing sugar and storing it as starch. It is present in the margin of leaves and resists tearing effect of the wind.
Glucokinase activity can be amplified or reduced in minutes by actions of the glucokinase regulatory protein (GKRP). The actions of this protein are influenced by small molecules such as glucose and fructose. The amount of glucokinase can be increased by synthesis of new protein. Insulin is the principal signal for increased transcription, operating mainly by way of a transcription factor called sterol regulatory element binding protein-1c (SREBP1c) in the liver. This occurs within an hour after a rise in insulin levels, as after a carbohydrate meal.
Sources: en.wikipedia.org
=== Resources created === CRAG: Computational resources for assembling genomes (CRAG) was created to assist users in assembling of genomes from short read sequencing (SRS). CRAG pursues the following major objectives: Collection and compilation of computation resources Brief description of genome assemblers Maintaining SRS and related data Service to community to assemble their genomes CRIP: Computational resources for predicting protein–macromolecular interactions (CRIP) was developed to provide resources related to interaction. This site maintains a large number of resources on the interaction of proteins that includes protein–protein, protein–DNA, protein–ligand, protein–RNA. BioTherapy: Bioinformatics for Therapeutic Peptides and Proteins (BioTherapi) was developed for researchers working in the field of protein/peptide therapeutics. The platform was created to provide a single platform for this area of research. This site includes relevant information about the use of peptides/proteins in drugs and synthesis of new peptides. It also covers problems in their formulation, synthesis and delivery processes. HIVbio: HIV Bioinformatics (HIVbio) site contains various types of information on Human Immunodeficiency Virus (HIV) life cycle and Infection.
Most Moluccans in northern Maluku (present-day province of North Maluku) are Muslim. Central and southern Maluku (present-day province of Maluku) have approximately equal numbers of Muslims and Christians. There is significant number of native Hindus (Tanimbar Kei people) living in the Kei Islands, which is a predominantly Catholic region. This is because, according to oral traditions, their ancestors came from Bal (Bali) during the Majapahit era. Additionally, they practice local customary law called Larvul Ngabal (transl. "red blood and spear from Bali"). The most common religion amongst Moluccans in the Netherlands is Protestantism, followed by Islam.
Born Mary Morse Baker on a farm in Bow, New Hampshire, Eddy was the youngest of six children in a family of Protestant Congregationalists. Her father, Mark Baker, was a deeply religious man, although, according to one account, "Christianity to him was warfare against sin, not a religion of human brotherhood." In common with most women at the time Eddy was given little formal education, but she said she had read widely at home. From childhood she lived with protracted ill health, complaining of chronic indigestion and spinal inflammation, and according to biographers experiencing fainting spells. The literary critic Harold Bloom described her as "a kind of anthology of nineteenth-century nervous ailments". Eddy's first husband died just before her 23rd birthday, six months after they married and three months before their son was born, leaving her penniless; as a result of her poor health she lost custody of the boy when he was four. Her second husband left her after 13 years of marriage; Eddy said that he had promised to become her child's legal guardian, but it is unclear whether he did, and Eddy lost contact with her son until he was in his thirties. (Per the legal doctrine of coverture, women in the United States could not then be their own children's guardians.) Her third husband, Asa Gilbert Eddy, died five years after they married; she believed he had been killed by malicious animal magnetism. Six years later, when she was 67 and apparently in need of loyalty and affection, she legally adopted a 41-year-old homeopath as her second son.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.